Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown. METHODS: A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound. RESULTS: After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p < 0.01 for all). Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by 18% (p < 0.01 for all lipid changes). Carotid IMT decreased from 1.19 ± 0.47 to 0.94 ± 0.21 mm (p < 0.01). Yet, changes in carotid IMT did not correlate with changes in any other variable studied. CONCLUSIONS: Liraglutide decreases carotid IMT after 8 months treatment independently of its effect on plasma glucose and lipids concentrations. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01715428.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575
Hogan, A. E., Gaoatswe, G., Lynch, L., Corrigan, M. A., Woods, C., O’Connell, J., & O’Shea, D. (2014) · Diabetologia · doi:10.1007/s00125-013-3145-0 · Cited by 239
Gaspari, T., Welungoda, I., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113481817 · Cited by 148
Ceriello, A., Esposito, K., Testa, R., Bonfigli, A. R., Marra, M., & Giugliano, D. (2011) · Diabetes Care · doi:10.2337/dc10-1949 · Cited by 134
Tesauro, M., Schinzari, F., Adamo, A., Rovella, V., Martini, F., Mores, N., Barini, A., Pitocco, D., Ghirlanda, G., Lauro, D., et al. (2013) · Diabetes Care · doi:10.2337/dc12-0763 · Cited by 54
Cited by
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
Rizzo, M., Nikolic, D., Patti, A. M., Mannina, C., Montalto, G., McAdams, B. S., Rizvi, A. A., & Cosentino, F. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.012 · Cited by 152
Self-citationRizzo, M., Rizvi, A. A., Patti, A. M., Nikolic, D., Giglio, R. V., Castellino, G., Li Volti, G., Caprio, M., Montalto, G., Provenzano, V., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0480-8 · Cited by 135
Self-citationRizzo, M., Abate, N., Chandalia, M., Rizvi, A. A., Giglio, R. V., Nikolic, D., Marino Gammazza, A., Barbagallo, I., Isenovic, E. R., Banach, M., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2291 · Cited by 113
Self-citation
Metadata
- Authors
- Rizzo, M., Chandalia, M., Patti, A. M., Di Bartolo, V., Rizvi, A. A., Montalto, G., & Abate, N.
- Venue
- Cardiovascular Diabetology
- Published
- 2014-02-22
- Volume
- 13
- Issue
- 1
- Pages
- 49-49
- ISSN
- 1475-2840 (ISSN-L)
- OpenAlex
- W2112912403
- Cited by
- 107
- References
- 8
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. https://app.cochat.ai/papers/10.1186/1475-2840-13-49
- The paper
- Rizzo, M., Chandalia, M., Patti, A. M., Di Bartolo, V., Rizvi, A. A., Montalto, G., & Abate, N. (2014). Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovascular Diabetology. https://doi.org/10.1186/1475-2840-13-49
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.